Nanobodies News and Research

RSS

NeutrobodyPlex nanobodies help monitor SARS-CoV-2 immune responses

Researchers recently described a set of 11 Nbs derived from an immunized alpaca which showed high-affinity binding to the glycosylated SARS-CoV-2 spike receptor domain (RBD) in a study published in the preprint server bioRxiv.

23 Sep 2020

Molecular dynamic simulations reveal detailed spike-ACE2 interactions

The current COVID-19 pandemic has spread throughout the world. Caused by a single-stranded RNA betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to but much more infectious than the earlier highly pathogenic betacoronaviruses SARS and MERS-CoV, has impacted social, economic, and physical health to an unimaginable extent.

23 Sep 2020

Study: Small neutralizing antibody can block SARS-CoV-2 from entering human cells

Researchers at Karolinska Institutet in Sweden have identified a small neutralizing antibody, a so-called nanobody, that has the capacity to block SARS-CoV-2 from entering human cells.

4 Sep 2020

Canadian Coalition for COVID-19 releases 51 promising nanobodies

A group of Canadian companies has published 51 antibodies that show promising ability to bind the COVID-19 virus which could result in neutralizing the virus.

From SignalChem Biotech Inc. 20 Aug 2020

Synthetic nanobodies prevent SARS-CoV-2 infection

A team of researchers from the University of California San Francisco has created a powerful nasal spray or inhaler that can provide high-grade protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The report is presently available on the bioRvix* preprint server.

13 Aug 2020

Inhaled delivery of a potent neutralizing nanobody effective against SARS-CoV-2

A recent study by researchers from China, available on the bioRxiv preprint server, shows how stable neutralizing nanobody Nb11-59 might be a promising prophylactic and therapeutic molecule against coronavirus disease (COVID-19) – especially if administered via the inhalatory route.

11 Aug 2020

Llama nanobodies block SARS-CoV-2 infection in vitro

Now, a team of scientists at the United Kingdom's Rosalind Franklin Institute may have a surprising solution for the coronavirus pandemic, which has killed more than 574,000 people worldwide.

14 Jul 2020

Absolute Antibody and University of Zurich partner to offer novel SARS-CoV-2 sybodies

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain (RBD) of SARS-CoV-2, the coronavirus that causes COVID-19.

From Absolute Antibody Ltd 14 Jul 2020

Integration of diverse set of species and environments can enhance biomedical research cycle

In an article published today in Science, a multidisciplinary research team from more than 10 universities and research institutes outlines how integrating a more diverse set of species and environments could enhance the biomedical research cycle.

3 Jul 2020

Effective neutralization of SARS-CoV-2 by synthetic nanobodies targeting the spike protein

In their recent bioRxiv paper, a multinational group of researchers reported rapid isolation and characterization of nanobodies from a synthetic library (known as sybodies) that target the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein – with a strikingly high neutralization ability.

24 Jun 2020

Canadian coalition prepares to share research that could help against COVID-19

A Canadian group of companies is sharing their results with the scientific community in the hopes of accelerating the development of tests for COVID-19.

From SignalChem Biotech Inc. 17 Jun 2020

How antibodies neutralize SARS-CoV-2 in convalescent patients

A new study by researchers from the United Kingdom and Taiwan and published on the preprint server bioRxiv in June 2020 describes the structural basis for the neutralizing effect of the SARS-CoV-2 antibody on the virus. This also indicates a possible therapeutic molecule by identifying its binding epitope as possibly a major neutralizing site.

16 Jun 2020